Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower pneumonia: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower pneumonia: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (AQLQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring hospital admission 49 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring hospital admission 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Lung function (change in trough FEV1 L) · adults with asthma
1 finding from 1 review
Intervention not reported
Asthma control (ACQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Any adverse events 49 weeks · adults with asthma
The intervention leads to lower any adverse events 49 weeks (high certainty).
1 finding from 1 review